Gilead Sciences | GILD - Trade Debtors


Gilead Sciences reported $5.06B in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
AbbVie USD 12.48B 110M Mar/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
ALKERMES USD 456.48M 48.85M Jun/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amgen USD 10.23B 1.09B Jun/2026
Biogen USD 1.79B 76.6M Mar/2026
BioMarin Pharmaceutical USD 1.06B 157.13M Jun/2026
Bristol-Myers Squibb USD 13.83B 535M Jun/2026
Coherus Biosciences USD 18.42M 232.08M Dec/2025
Eli Lilly USD 23.48B 2.3B Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.07B 137M Jun/2026
Glaxosmithkline GBP 10.49B 40.6M Mar/2026
Incyte USD 1.13B 73.7M Jun/2026
J&J USD 22.54B 1.21B Mar/2026
Merck USD 12.21B 435M Mar/2026
Moderna USD 17M 54M Jun/2026
Neurocrine Biosciences USD 887M 118.9M Jun/2026
Novartis USD 9.85B 252M Jun/2026
Pfizer USD 16.19B 19M Jun/2026
PTC Therapeutics USD 219.92M 38.3M Mar/2026
Puma Biotechnology USD 28.1M 3.52M Jun/2024
Regeneron Pharmaceuticals USD 6.57B 834.4M Jun/2026
Sangamo BioSciences USD 581K 110K Jun/2024
Sanofi EUR 492M 10M Jun/2026
Sarepta Therapeutics USD 393.8M 154.11M Jun/2026
United Therapeutics USD 310.3M 1.7M Jun/2026
Vertex Pharmaceuticals USD 2.13B 138.2M Jun/2026